What is the role of autoimmunity in type 1 diabetes? A clinical perspective

Diabetologia

Volumn 57, Issue 4, 2014, Pages 653-655

  Donath, Marc Y ^a   Hess, Christoph ^a   Palmer, Ed ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Autoimmunity; Beta cells; Clinic; Type 1 diabetes

Indexed keywords

AUTOANTIBODY; CD20 ANTIBODY; CD3 ANTIBODY; CYCLOSPORIN A; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HEMOGLOBIN A1C; HYBRID PROTEIN; IMMUNOGLOBULIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA ANTIBODY; PLACEBO; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

ABDOMINAL DISCOMFORT; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CLINICAL TRIAL (TOPIC); CROHN DISEASE; DIARRHEA; FOLLOW UP; GENOTYPE; GINGIVA HYPERPLASIA; HISTOPATHOLOGY; HLA SYSTEM; HUMAN; HYPERGLYCEMIA; HYPERTRICHOSIS; IMMUNE SYSTEM; INFECTION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; PANCREAS ISLET BETA CELL; PATHOGENESIS; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME; VOMITING;

ANIMALS; AUTOIMMUNITY; DIABETES MELLITUS, TYPE 1; HUMANS; INSULIN-SECRETING CELLS;

EID: 84896077776     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-013-3153-0     Document Type: Note

References (24)

1. Campbell-Thompson ML, Atkinson MA, Butler AE et al (2013) The diagnosis of insulitis in human type 1 diabetes. Diabetologia 56: 2541-2543
2. In't Veld P, Lievens D, de Grijse J et al (2007) Screening for insulitis in adult autoantibody-positive organ donors. Diabetes 56:2400-2404 (Pubitemid 47358248)
3. Coppieters KT, Dotta F, Amirian N et al (2012) Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients. J Exp Med 209:51-60
4. Willcox A, Richardson SJ, Bone AJ, Foulis AK, Morgan NG (2009) Analysis of islet inflammation in human type 1 diabetes. Clin Exp Immunol 155:173-181
5. In't Veld P, de Munck N, van Belle K et al (2010) Beta-cell replication is increased in donor organs from young patients after prolonged life support. Diabetes 59:1702-1708
6. Skog O, Korsgren S, Melhus A, Korsgren O (2013) Revisiting the notion of type 1 diabetes being a T cell-mediated autoimmune disease. Curr Opin Endocrinol Diabetes Obes 20:118-123
7. Lahmar A, Mzabi-Regaya S, Boubaker S, Kchir N, Hendaoui L (2012) Systemic vasculitis: anatomy and histopathology. In: Hendaoui L, Stanson AW, Habib Bouhaouala M, Joffre F (eds) Systemic vasculitis. Springer, Heidelberg, pp 15-23
8. Cui Z, Zhao MH (2011) Advances in human antiglomerular basement membrane disease. Nat Rev Nephrol 7:697-705
9. The Canadian-European Randomized Control Trial Group (1988) Cyclosporin-induced remission of IDDM after early intervention. Association of 1 yr of cyclosporin treatment with enhanced insulin secretion. Diabetes 37:1574-1582
10. Feutren G, Papoz L, Assan R et al (1986) Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Results of a multicentre double-blind trial. Lancet 2: 119-124
11. Mandrup-Poulsen T, Nerup J, Stiller CR et al (1985) Disappearance and reappearance of islet cell cytoplasmic antibodies in cyclosporin-treated insulin-dependent diabetics. Lancet 1:599-602 (Pubitemid 15133882)
12. Orban T, Bundy B, Becker DJ et al (2011) Co-stimulationmodulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet 378: 412-419
13. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H et al (2009) Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 361:2143-2152
14. Herold KC, Hagopian W, Auger JA et al (2002) Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 346:1692-1698 (Pubitemid 34547482)
15. Keymeulen B, Vandemeulebroucke E, Ziegler AG et al (2005) Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 352:2598-2608 (Pubitemid 41007846)
16. Sherry N, Hagopian W, Ludvigsson J et al (2011) Teplizumab for treatment of type 1 diabetes (Protege study): 1-year results from a randomised, placebo-controlled trial. Lancet 378:487-497
17. Huurman VA, Decochez K, Mathieu C, Cohen IR, Roep BO (2007) Therapy with the hsp60 peptide DiaPep277 in C-peptide positive type 1 diabetes patients. Diabetes Metab Res Rev 23:269-275 (Pubitemid 46851467)
18. Mastrandrea L, Yu J, Behrens T et al (2009) Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study. Diabetes Care 32: 1244-1249
19. Moran A, Bundy B, Becker DJ et al (2013) Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet 381:1905-1915
20. Targan SR, Hanauer SB, van Deventer SJ et al (1997) A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 337:1029-1035
21. Greenbaum CJ, Beam CA, Boulware D et al (2012) Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data. Diabetes 61: 2066-2073
22. Brooks-Worrell B, Narla R, Palmer JP (2012) Biomarkers and immune-modulating therapies for type 2 diabetes. Trends Immunol 33:546-553
23. Concannon P, Rich SS, Nepom GT (2009) Genetics of type 1A diabetes. N Engl J Med 360:1646-1654
24. Sutherland DE, Goetz FC, Sibley RK (1989) Recurrence of disease in pancreas transplants. Diabetes 38(Suppl 1):85-87 (Pubitemid 19029246)